

Linking *SIRT1* gene variation and protein levels to the Pathophysiology of type 2 diabetes

Hayder Hasan Idan¹, Leila Kohan^{2,*}

1) Department of Biology, Shi.C., Islamic Azad University, Shiraz, Iran

2) Department of Biology, Ars.C., Islamic Azad University, Arsanjan, Iran

Table S1: Primer sequences and expected product sizes used for genotyping of SIRT1 rs7895833

Primer	5' to 3'	Product size (bp)
FI(Allele A)	GTGGTAAAAGGCCTACAGGCAA	301
RI(Allele G)	CTTGCTTCCTAATCTCCATTACGTTTAC	201
FO	CCTAGCTGGTCTATCTCCCTTACCTC	453
RO	GCACATCTGTGTATCCCCTAGAAAG	453

Table S2: Demographic, anthropometric, and biochemical characteristics of participants in the T2DM and control groups

Group/Parameter	T2DM <i>n</i> =150	Control <i>n</i> =150	<i>P</i> -value
Age (year)	41.71±6.12	40.35±6.70	0.069
Gender M/F	66/84	72/78	0.489
BMI (kg/m ²)	26.94±4.61	23.65±3.42	<0.001
FPG (mg/dl)	178.47±28.19	92.9±7.80	<0.001
HbA _{1c} (%)	10.15±2.06	5.13±0.61	<0.001
Insulin (μIU/ml)	11.54±2.63	7.91±1.65	<0.001
HOMA-IR	5.26±2.03	1.81±0.41	<0.001
TG (mg/dl)	187.65±41.90	167.59±39.19	<0.001
TC (mg/dl)	187.28±32.58	182.63±29.51	0.196
HDL (mg/dl)	39.69±3.14	39.96±4.14	0.530
LDL (mg/dl)	110.06±32.18	109.15±30.57	0.803
VLDL (mg/dl)	37.53±8.38	33.52±7.84	<0.001
Urea (mg/dl)	36.64±5.53	35.47±5.43	0.065
Creatinine (mg/dl)	0.677±0.179	0.653±0.173	0.226

BMI: Body Mass Index; FPG: Fasting Plasma Glucose; HbA_{1c}: HemoglobinA_{1c}; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; TG: Triglycerides; TC: Total Cholesterol; HDL: High-Density Lipoprotein; LDL: Low-Density Lipoprotein; VLDL: Very-Low-Density Lipoprotein.